Mifcare & Inserm enter into Partnership
- Published on 22 April 2014
Paris, April 22, 2014 - MIFCARE and INSERM have signed a research partnership agreement in the field of pulmonary hypertention (PH) aiming to identify new small molecule MIF inhibitors for the treatment of pulmonary arterial hypertension (PAH).
Creation of Mifcare
- Published on 31 July 2013
Mifcare was founded in July 2013 to develop innovative drugs that address significant unmet medical needs in the field of chronic inflammation, with a primary focus on Pulmonary arterial hypertension (PAH).The company is specialized in the discovery and development of new small molecule targeting macrophage migration inhibitory factor (MIF), a pleiotropic cytokine that modulates pro-inflammatory immune responses. Mifcare is located at 24 rue du Faubourg Saint-Jacques, 75014, Paris, France.
Mifcare is recipient of 2013 i-LAB innovation prize
- Published on 04 June 2013
Mifcare was awarded at the i-LAB « National contest for the creation of innovative technology companies » organized by Bpifrance and French Ministry for Higher Education and Research.
Mifcare is incubated at Paris Biotech Santé
- Published on 28 May 2013
Mifcare is incubated at Paris Biotech Santé, a French businesss accelerator specialized in drug development, medical devices and innovative services for the benefit of patients. Paris Biotech Santé is located at Cochin Hospital and Faculty of Medicine René Descartes.